Lymphocyte T-Cell Immunomodulator (LTCI) presents a revolutionary, USDA-approved treatment option for osteoarthritis in dogs. In a pivotal clinical trial, over 90% of LTCI patients achieved significant improvements in symptoms. Additional benefits of LTCI include: Increased mobility; Reduced lymphocytosis; Well tolerated

LTCI is the first and only USDA-approved treatment aid for cats infected with Feline Leukemia Virus (FeLV) and/or Feline Immunodeficiency Virus (FIV). And now, LTCI is the first USDA-approved immune modulator for treatment of osteoarthritis in dogs.

LTCI, a naturally-occurring biologic, is the first USDA-approved immune modulator for treating canine osteoarthritis. Osteoarthritis–as an immune-mediated disease–should be treated as such.

2011年5月31日 · Veterinarians may now order Lymphocyte T-Cell Immunomodulator (LTCI) -- reportedly the first United States Department of Agriculture (USDA) approved treatment for Feline Leukemia Virus (FeLV) and Feline Immunodeficiency Virus (FIV) -- directly from the manufacturer, T-Cyte Therapeutics.

T-Cyte Therapeutics provides USDA-approved, innovative treatment solutions that safely address the needs of pets with immune-mediated diseases, such as osteoarthritis. T-Cyte is dedicated to...

2016年10月6日 · T-Cyte Therapeutics, Inc., today announces the U.S. launch of Lymphocyte T-Cell Immunomodulator (LTCI) as the first USDA-approved treatment option for canine osteoarthritis (OA), a debilitating condition affecting 16-20 million dogs in the U.S. alone. The only biologic treatment aid for OA, LTCI is administered by veterinarians via an injection ...

Technocyte病毒 (亦被简称为T-Cyte) 是游戏中一种极其危险且具有感染性的病毒。 尽管其来源并不明确，但大部分的信息均显示，这种病毒来源于美国，并且 Yargo Mensik 参与了其中的研发，然而关于它的许多信息仍然是谜。

2014年5月21日 · T-Cyte Treatment is treating cats who have FeLV and/or FIV with Lymphocyte T-Cell Immunomodulator. T-Cyte Therapeutics is the name of the manufacturer who supply vets with this expensive treatment. They are not very open about its success rate and cost etc..

2016年10月6日 · Now, T-Cyte provides the only treatment aid for cats infected with FeLV and FIV and has expanded its treatment options to canines, with LTCI functioning as the first USDA-approved immune modulator for treatment of osteoarthritis in dogs.

As a naturally-occurring, immune-modulating protein, LTCI is the first USDA-approved treatment aid for osteoarthritis in dogs. The long prevailing understanding of osteoarthritis (OA) has been that of an age-related degenerative disease caused by “wear and tear”, in contrast to the immune mediated cause of rheumatoid arthritis (RA).